Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Femasys Inc. (FEMY)

1.3700 +0.0600 (+4.58%)
At close: November 6 at 4:00:01 PM EST
Chart Range Bar
Loading chart for FEMY
Chart does not reflect overnight price.
  • Previous Close 1.3100
  • Open 1.3200
  • Bid 1.3100 x 100
  • Ask 2.5900 x 200
  • Day's Range 1.3000 - 1.4100
  • 52 Week Range 1.2550 - 22.2000
  • Volume 72,720
  • Avg. Volume 725,129
  • Market Cap (intraday) 11.474M
  • Beta (5Y Monthly) -2.17
  • PE Ratio (TTM) --
  • EPS (TTM) -3.2800
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 16.50
  • Moby Rating Neutral

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

femasys.com

51

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

FEMY
88.11%
S&P 500 (^GSPC)
7.76%

1-Year Return

FEMY
91.23%
S&P 500 (^GSPC)
9.77%

3-Year Return

FEMY
94.73%
S&P 500 (^GSPC)
68.96%

5-Year Return

FEMY
99.06%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 424.89k
Earnings 328.65k
Profit Margin 77.35%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-4M
-3M
-2M
-1M
0
-1000.0%
-800.0%
-600.0%
-400.0%
-200.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
16.50 Average
1.3700 Current
23.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/18/2026
Analyst Lake Street
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 30 -> 10

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -84.22%

  • Return on Equity (ttm)

    -424.97%

  • Revenue (ttm)

    2.3M

  • Net Income Avi to Common (ttm)

    -11.77M

  • Diluted EPS (ttm)

    -3.2800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.44M

  • Total Debt/Equity (mrq)

    118.84%

  • Levered Free Cash Flow (ttm)

    -11.23M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: